- Home
- NPCE vs LYEL Comparison
NPCE vs LYEL Comparison
Compare NPCE & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPCE | LYEL |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | N/A | 300 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 514.3M | 490.1M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NPCE | LYEL |
|---|---|---|
| Price | $14.75 | $23.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $18.33 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 143.6K | 91.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.77 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $79,906,000.00 | $61,000.00 |
| Revenue This Year | $25.95 | N/A |
| Revenue Next Year | $0.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.14 | N/A |
| 52 Week Low | $7.56 | $0.39 |
| 52 Week High | $18.97 | $45.00 |
Technical Indicators
Market Signals| Indicator | NPCE | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 41.93 | 46.62 |
| Support Level | $14.02 | $21.27 |
| Resistance Level | $16.96 | $27.30 |
| Average True Range (ATR) | 0.71 | 2.57 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 25.05 | 45.35 |
Price Performance
Historical ComparisonAbout NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.